Nico Vandervelpen is managing director and co-founder of bioqube ventures. In 2016, bioqube ventures partnered with Janssen Pharmaceutica NV (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to act as the independent management arm leading the new Johnson & Johnson Innovation, JLINX initiative. Through this partnership, bioqube ventures will run the day to day operations of JLINX, including managing the investment portfolio and relationships with external venture investors, involvement in identifying, securing and investing in new companies, and supporting the overall scale-up of the new initiative.
Nico previously served in a variety of capacities at LRM, a Belgium-based private equity and venture capital firm, including most recently as the funds Chief Operating Officer. Prior to joining LRM, between 1998 and 2007, Nico was a senior executive at Ernst & Young.
Nico served on the board of directors of several public and private life sciences companies and has led several dozen international venture capital transactions and M&A deals including Minerva Neurosciences (Nasdaq: NERV), Tigenix (NYSE Euronext: TIG), SEPS Pharma (acquired by Amatsi) and Apitope. Nico holds a Masters degree in commercial and business engineering from Hasselt University as well as a Master in Accountancy from VLEKHO Business School - Brussels.